Barely Significant

Excerpts

5,102 sentences · 1 filter applied

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has emerged in recent years as a novel alternative approach to conventional Redo surgical aortic valve replacement (Redo-SAVR) resulting in an increasing trend toward implantation of biological valves at primary surgical aortic valve replacement (SAVR), even in younger patients.
The first interim analysis, at a median follow-up of 17.9 months, showed a statistically significant improvement in PFS (24-month PFS was 67.8% with pembrolizumab + CCRT versus 57.3% with placebo + CCRT) and a favorable trend in OS (HR = 0.73) for the combination pembrolizumab and CCRT compared with placebo and CCRT, with a manageable safety profile.
The pooled analysis showed an increasing trend towards more pacemaker implantations in the TAVI group, but this difference was not statistically significant (OR 0.76; 95% CI: 0.48−1.19; p = 0.23; Figure 2 C).